222 related articles for article (PubMed ID: 31970799)
1. Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation.
Seike K; Fujii N; Asano N; Ohkuma S; Hirata Y; Fujii K; Sando Y; Nakamura M; Naito K; Saeki K; Meguri Y; Asada N; Ennishi D; Nishimori H; Matsuoka KI; Tsubaki K; Otsuka F; Maeda Y
Transfusion; 2020 Mar; 60(3):473-478. PubMed ID: 31970799
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
Wiita AP; Nambiar A
Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
[TBL] [Abstract][Full Text] [Related]
3. Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients.
Gavva C; Barroso J; Gernsheimer T; Metcalf RA; Warner P; Pagano MB
Transfusion; 2019 Jul; 59(7):2276-2281. PubMed ID: 31032968
[TBL] [Abstract][Full Text] [Related]
4. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion.
Rioux-Massé B; Cohn C; Lindgren B; Pulkrabek S; McCullough J
Transfusion; 2014 Dec; 54(12):3080-7. PubMed ID: 24916382
[TBL] [Abstract][Full Text] [Related]
5. HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients.
Mirlashari MR; Vetlesen A; Nissen-Meyer LSH; Naper C; Tjønnfjord GE; Njerve IU; Ezligini F; Landmark BF; Meinke S; Sandgren P; Höglund P; Hetland G
Transfusion; 2021 Apr; 61(4):1222-1234. PubMed ID: 33580979
[TBL] [Abstract][Full Text] [Related]
6. A case of platelet transfusion refractoriness due to anti-CD36 with a successful treatment outcome.
Khatri SS; Curtis BR; Yamada C
Immunohematology; 2019 Dec; 35(4):139-144. PubMed ID: 31935329
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
[TBL] [Abstract][Full Text] [Related]
8. Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review.
Vassallo RR; Fung M; Rebulla P; Duquesnoy R; Saw CL; Slichter SJ; Tanael S; Shehata N;
Transfusion; 2014 Apr; 54(4):1180-91. PubMed ID: 24032995
[TBL] [Abstract][Full Text] [Related]
9. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review.
Pavenski K; Rebulla P; Duquesnoy R; Saw CL; Slichter SJ; Tanael S; Shehata N;
Transfusion; 2013 Oct; 53(10):2230-42. PubMed ID: 23550773
[TBL] [Abstract][Full Text] [Related]
11. Platelet transfusion refractoriness after T-cell-replete haploidentical transplantation is associated with inferior clinical outcomes.
Fu Q; Xu L; Zhang X; Wang Y; Chang Y; Liu K; Huang X
Sci China Life Sci; 2018 May; 61(5):569-577. PubMed ID: 28914433
[TBL] [Abstract][Full Text] [Related]
12. Recipient-derived HPA-1a antibodies: a cause of prolonged thrombocytopenia after unrelated donor stem cell transplantation.
Lucas G; Culliford S; Green F; Sidra G; Calvert A; Green A; Harrison P; Harvey J; Allen D; Smillie D; Masurekar A; Marks D; Russell N; Massey E
Transfusion; 2010 Feb; 50(2):334-9. PubMed ID: 19874563
[TBL] [Abstract][Full Text] [Related]
13. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
14. Pre-transplant thrombocytopenia predicts engraftment time and blood products requirement in allogeneic hematopoietic stem cell transplantation patients.
Roshandel E; Kaviani S; Hajifathali A; Soleimani M
Transfus Apher Sci; 2020 Aug; 59(4):102810. PubMed ID: 32430259
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Efficacy of Platelet Transfusion and Analysis of Influencing Factors in 364 patients.
Sun X; Cai Y; Ni H; Cong H
Acta Haematol; 2023; 146(3):214-219. PubMed ID: 36758527
[TBL] [Abstract][Full Text] [Related]
16. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model.
Gras C; Schulze K; Goudeva L; Guzman CA; Blasczyk R; Figueiredo C
Hum Gene Ther; 2013 Dec; 24(12):1018-28. PubMed ID: 24090417
[TBL] [Abstract][Full Text] [Related]
17. Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases.
Song X; Qi J; Li X; Zhou M; He J; Chu T; Han Y
Platelets; 2023 Dec; 34(1):2229905. PubMed ID: 37409458
[TBL] [Abstract][Full Text] [Related]
18. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.
Murphy S; Snyder E; Cable R; Slichter SJ; Strauss RG; McCullough J; Lin JS; Corash L; Conlan MG;
Transfusion; 2006 Jan; 46(1):24-33. PubMed ID: 16398727
[TBL] [Abstract][Full Text] [Related]
19. The investigation of platelet transfusion refractory in 69 malignant patients undergoing hematopoietic stem cell transplantation.
Li G; Liu F; Mao X; Hu L
Transfus Apher Sci; 2011 Aug; 45(1):21-4. PubMed ID: 21798807
[TBL] [Abstract][Full Text] [Related]
20. Peripartum management of HLA alloimmune platelet refractoriness.
Peña JR; Sudhof L; O'Brien B
Transfusion; 2018 Jul; 58(7):1583-1587. PubMed ID: 29664113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
